Search Results 1511-1520 of 17470 for magnesiummagnesium

1. Study of Pembrolizumab Combined with Decitabine and Pralatrexate in Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma - Mayo Clinic

   > 2.5 mg/dL. Coagulation. International Normalized Ratio (INR) or Prothrombin Time (PT). ≤ 1.5 X ULN unless subject is receiving anticoagulant therapy as ...

2. Study to Evaluate the Safety, Tolerability and Preliminary Antitumor Activity of INCB059872 in Patients with Relapsed/Refractory Ewing Sarcoma - Mayo Clinic

   ... mg/day) or off of all corticosteroids for at least 2 weeks before the first dose of study treatment. Prior radiotherapy within 2 weeks of study treatment ...

3. A Study to Compare CMP-001 Combined with Nivolumab to Nivolumab Alone in Advanced Melanoma Subjects - Mayo Clinic

   Subjects who are currently receiving steroids at a prednisone-equivalent dose of ≤10 mg/day do not need to discontinue steroids prior to enrollment; ...

4. A Study of TAK-981 in Combination with Rituximab in Participants with Relapsed/Refractory (r/r) CD20-positive (CD20+) Non-Hodgkin Lymphoma (NHL) - Mayo Clinic

   Active, uncontrolled autoimmune disease requiring > 20 mg of prednisone or equivalent, cytotoxics or biologicals. Corticosteroid use within 1 week before ...

5. Mayo Clinic Minute: Low testosterone levels can affect men

   It's a hormone that makes men masculine. But it's often the one that causes the most confusion for men. So much of a man's physical characteristics are ...

6. Publications - Santo Maimone, IV, M.D. - Mayo Clinic

   ... MG, McLaughlin SA, Pockaj BA, Chen B, Musonza T, Harmsen WS, Boughey JC, Hieken TJ, Habermann EB, Shah HN, Degnim AC. A Validated Nomogram to Predict ...

7. Doxorubicin Hydrochloride, Cyclophosphamide, And Paclitaxel With Or Without Bevacizumab In Treating Patients With Lymph Node-Positive Or High-Risk, Lymph Node-Negative Breast Cancer - Mayo Clinic

   ... mg/dL. Within =< 8 weeks prior to randomization: Aspartate aminotransferase (AST) =< 2 times upper limit of normal(ULN). Within =< 8 weeks prior to ...

8. A Study to Evaluate the Effectiveness and Safety of Vedolizumab to Treat Chronic Pouchitis - Mayo Clinic

   A tuberculin skin test reaction ≥ 10 mm (≥ 5 mm in participants receiving the equivalent of > 15 mg/day prednisone); OR; Chest X-ray within 3 months prior ...

9. Study to Evaluate the Efficacy and Safety of Ersodetug in Patients With Inadequately Controlled Hypoglycemia Due to Tumor-Associated Hyperinsulinism - Mayo Clinic

   Experiencing an average of ≥ 3 hypoglycemia events per week that meet Level 2 (blood glucose < 54 mg/dL [< 3 mmol/L] by SMBG) and/or Level 3 (events ...

10. Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer - Mayo Clinic

    Low dose warfarin (1 mg orally, once daily) with INR/PTT ≤ 1.5 x ULN is permitted; infrequent bleeding or elevations in INR/PTT have been reported in some ...